Safety and efficacy of long-term outpatient ertapenem therapy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3437-3440

  Qureshi, Zubair A ^a   Syed, Alveena ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN; BETA LACTAM;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDES INFECTION; BLOODSTREAM INFECTION; BONE AND JOINT INFECTIONS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMPYEMA; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI INFECTION; FOLLOW UP; FUSOBACTERIUM INFECTION; GRAFT INFECTION; GRAM POSITIVE INFECTION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDIASTINITIS; MONOTHERAPY; OSTEOMYELITIS; OUTPATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; PROTEUS INFECTION; PYELONEPHRITIS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SERRATIA INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; SURGICAL INFECTION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; ARTHRITIS, INFECTIOUS; BACTERIAL PNEUMONIA; BONE; COHORT ANALYSIS; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; OUTPATIENT; SKIN; SOFT TISSUE INFECTIONS; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, INFECTIOUS; BETA-LACTAMS; BONE AND BONES; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INTRAABDOMINAL INFECTIONS; MIDDLE AGED; OUTPATIENTS; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SKIN; SOFT TISSUE INFECTIONS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901268347     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02721-14     Document Type: Article

References (15)

1. Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R. 2004. Safety and tolerability of ertapenem. J. Antimicrob. Chemother. 53(Suppl 2):ii75-ii81. http://dx.doi.org/10.1093/jac/dkh209.
2. Shah PM, Isaacs RD. 2003. Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. 52:538-542. http://dx.doi.org/10.1093/ jac/dkg404.
3. Gesser RM, McCarroll KA, Woods GL. 2004. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J. Infect. 48:32-38. http://dx.doi.org/10.1016/j.jinf.2003.10.001.
4. Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, Scaglione F, International OPAT Registry. 2004. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int. J. Antimicrob. Agents 24:473-478. http://dx.doi.org/10.1016/j.ijantimicag.2004.06.004.
5. MacKenzie M, Rae N, Nathwani D. 2014. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. Int. J. Antimicrob. Agents 43:7-16. http://dx.doi.org/10.1016/j. ijantimicag.2013.09.006.
6. Nathwani D, Tice A. 2002. Ambulatory antimicrobial use: the value of an outcomes registry. J. Antimicrob. Chemother. 49:149-154. http://dx.doi.org/10. 1093/jac/49.1.149.
7. Seaton RA, Barr DA. 2013. Outpatient parenteral antibiotic therapy: principles and practice. Eur. J. Intern. Med. 24:617-623. http://dx.doi.org/10. 1016/j.ejim.2013.03.014.
8. Bazaz R, Chapman AL, Winstanley TG. 2010. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-lactamase-producing Gram-negative organisms. J. Antimicrob. Chemother. 65:1510-1513. http://dx.doi.org/10.1093/jac/dkq152.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. http://dx.doi.org/10.1016/0021-9681(87) 90171-8.
10. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-Associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
12. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. 2013. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gramnegative infections: a systematic review. Expert Rev. Anti Infect. Ther. 11:69-78. http://dx.doi.org/10.1586/eri.12.149.
13. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. 2010. Epidemiologic trends, occurrence of extended-spectrum-lactamase production, and performance of ertapenem and comparators in patients with intraabdominal infections: analysis of global trend data from 2002-2007 from the SMART study. Surg. Infect. 11:371-378. http://dx.doi.org/10.1089/sur.2009.057.
14. Goswami ND, Johnson MD, Chu VH. 2011. Ertapenem for treatment of osteomyelitis: a case series. BMC Res. Notes 4:478. http://dx.doi.org/10.1186/ 1756-0500-4-478.
15. Gilbert DN, Dworkin RJ, Raber SR, Leggett JE. 1997. Outpatient parenteral antimicrobial-drug therapy. N. Engl. J. Med. 337:829-838. http://dx.doi.org/10. 1056/NEJM199709183371207.